116 results on '"Joon Yong Bae"'
Search Results
2. Seroepidemiologic survey of emerging vector-borne infections in South Korean forest/field workers.
- Author
-
Ji Yun Noh, Joon Young Song, Joon Yong Bae, Man-Seong Park, Jin Gu Yoon, Hee Jin Cheong, and Woo Joo Kim
- Subjects
Arctic medicine. Tropical medicine ,RC955-962 ,Public aspects of medicine ,RA1-1270 - Abstract
With global warming and lush forest change, vector-borne infections are expected to increase in the number and diversity of agents. Since the first report of severe fever with thrombocytopenia syndrome (SFTS) in 2013, the number of reported cases has increased annually in South Korea. However, although tick-borne encephalitis virus (TBEV) was detected from ticks and wild rodents, there is no human TBE case report in South Korea. This study aimed to determine the seroprevalence of TBEV and SFTS virus (SFTSV) among forest and field workers in South Korea. From January 2017 to August 2018, a total 583 sera were obtained from the forest and field workers in South Korea. IgG enzyme-linked immunosorbent assay (ELISA) and neutralization assay were conducted for TBEV, and indirect immunofluorescence assay (IFA) and neutralization assay were performed for SFTSV. Seroprevalence of TBEV was 0.9% (5/583) by IgG ELISA, and 0.3% (2/583) by neutralization assay. Neutralizing antibody against TBEV was detected in a forest worker in Jeju (1:113) and Hongcheon (1:10). Only 1 (0.2%) forest worker in Yeongju was seropositive for SFTSV by IFA (1:2,048) and neutralizing antibody was detected also. In conclusion, this study shows that it is necessary to raise the awareness of physicians about TBEV infection and to make efforts to survey and diagnose vector-borne diseases in South Korea.
- Published
- 2021
- Full Text
- View/download PDF
3. Development and Validation of an Enzyme-Linked Immunosorbent Assay-Based Protocol for Evaluation of Respiratory Syncytial Virus Vaccines
- Author
-
Eliel Nham, A-Yeung Jang, Hyun Jung Ji, Ki Bum Ahn, Joon-Yong Bae, Man-Seong Park, Jin Gu Yoon, Hye Seong, Ji Yun Noh, Hee Jin Cheong, Woo Joo Kim, Ho Seong Seo, and Joon Young Song
- Subjects
respiratory syncytial virus ,RSV ,ELISA ,vaccine ,immunogenicity ,Microbiology ,QR1-502 - Abstract
Recently, respiratory syncytial virus (RSV) vaccines based on the prefusion F (pre-F) antigen were approved in the United States. We aimed to develop an enzyme-linked immunosorbent assay (ELISA)-based protocol for the practical and large-scale evaluation of RSV vaccines. Two modified pre-F proteins (DS-Cav1 and SC-TM) were produced by genetic recombination and replication using an adenoviral vector. The protocol was established by optimizing the concentrations of the coating antigen (pre-F proteins), secondary antibodies, and blocking buffer. To validate the protocol, we examined its accuracy, precision, and specificity using serum samples from 150 participants across various age groups and the standard serum provided by the National Institute of Health. In the linear correlation analysis, coating concentrations of 5 and 2.5 μg/mL of DS-Cav1 and SC-TM showed high coefficients of determination (r > 0.90), respectively. Concentrations of secondary antibodies (alkaline phosphatase-conjugated anti-human immunoglobulin G, diluted 1:2000) and blocking reagents (5% skim milk/PBS-T) were optimized to minimize non-specific reactions. High accuracy was observed for DS-Cav1 (r = 0.90) and SC-TM (r = 0.86). Further, both antigens showed high precision (coefficient of variation < 15%). Inhibition ELISA revealed cross-reactivity of antibodies against DS-Cav1 and SC-TM, but not with the attachment (G) protein.
- Published
- 2024
- Full Text
- View/download PDF
4. Performance evaluation of newly developed surrogate virus neutralization tests for detecting neutralizing antibodies against SARS-CoV-2
- Author
-
Oh Joo Kweon, Joon-Yong Bae, Yong Kwan Lim, Yoojeong Choi, Sohyun Lee, Man-Seong Park, In Bum Suh, Hana Kim, Young Sam Jee, and Mi-Kyung Lee
- Subjects
Medicine ,Science - Abstract
Abstract We evaluated newly developed surrogate virus neutralization tests (sVNT) for detecting neutralizing antibodies (NAbs) against the receptor binding domain of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). VERI-Q SARS-CoV-2 Neutralizing Antibody Detection ELISA Kit (MiCo BioMed, Gyeonggi-do, Republic of Korea, hereafter, “eCoV-CN”) is an enzyme-linked immunosorbent assay-based sVNT, and VERI-Q SARS-CoV-2 Neutralizing Antibody Rapid Test Kit (MiCo BioMed, hereafter, “rCoV-RN”) is a point-of-care lateral-flow immunochromatography test with auto-scanner. A total of 411 serum samples were evaluated. Both evaluations used a 50% plaque reduction neutralization test (PRNT50) as the gold standard. Compared with PRNT50, the eCoV-CN showed 98.7% positive percent agreement (PPA), 96.8% negative percent agreement (NPA), 97.4% total percent agreement (TPA), with kappa values of 0.942. The rCoV-RN showed 98.7% PPA, 97.4% NPA, 97.8% TPA, and kappa values of 0.951, comparing to PRNT50. Neither assay indicated cross-reactivity for other pathogens, and the signal indexes were statistically significantly correlated to the PRNT50 titer. The two evaluated sVNTs show comparable performances to the PRNT50 with the advantages of technical simplicity, speed, and do not require cell culture facilities.
- Published
- 2023
- Full Text
- View/download PDF
5. Age-Stratified Seroprevalence of Respiratory Syncytial Virus: Analysis Using Prefusion F and G Protein Antibodies
- Author
-
Eliel Nham, A-Yeung Jang, Hakjun Hyun, Jin Gu Yoon, Ji Yun Noh, Hee Jin Cheong, Woo Joo Kim, Ki Bum Ahn, Hyun Jung Ji, Ho Seong Seo, Joon-Yong Bae, Man-Seong Park, and Joon Young Song
- Subjects
respiratory syncytial virus ,RSV ,seroprevalence ,antibody ,Medicine - Abstract
This is a cross-sectional serosurveillance study for RSV. Between June and September of 2021, a total of 150 sera were collected from 30 individuals in each age group (
- Published
- 2024
- Full Text
- View/download PDF
6. Mutational analysis of severe acute respiratory syndrome coronavirus 2 in immunocompromised patients with persistent viral detection using whole genome sequencing
- Author
-
Euijin Chang, Jungmin Lee, Jun‐Won Kim, Jong Hyeon Seok, Joon‐Yong Bae, Jeonghun Kim, Heedo Park, Choi‐Young Jang, Sung‐Woon Kang, So Yun Lim, Ji Yeun Kim, Jeong‐Sun Yang, Kyung‐Chang Kim, Joo‐Yeon Lee, Man‐Seong Park, and Sung‐Han Kim
- Subjects
Medicine (General) ,R5-920 - Published
- 2023
- Full Text
- View/download PDF
7. Genome-informed investigation of the molecular evolution and genetic reassortment of severe fever with thrombocytopenia syndrome virus.
- Author
-
Kyuyoung Lee, Jong Hyeon Seok, Hyunbeen Kim, Sejik Park, Sohyun Lee, Joon-Yong Bae, Kyeongseok Jeon, Jun-Gu Kang, Jeong Rae Yoo, Sang Taek Heo, Nam-Hyuk Cho, Keun Hwa Lee, Kisoon Kim, Man-Seong Park, and Jin Il Kim
- Subjects
Arctic medicine. Tropical medicine ,RC955-962 ,Public aspects of medicine ,RA1-1270 - Abstract
BackgroundSevere fever with thrombocytopenia syndrome virus (SFTSV) is a viral pathogen causing significant clinical signs from mild fever with thrombocytopenia to severe hemorrhages. World Health Organization has paid special attention to the dramatic increase in human SFTS cases in China, Japan, and South Korea since the 2010s. The present study investigated the molecular evolution and genetic reassortment of SFTSVs using complete genomic sequences.Methods/principal findingWe collected the complete genome sequences of SFTSVs globally isolated until 2019 (L segment, n = 307; M segment, n = 326; and S segment, n = 564) and evaluated the evolutionary profiles of SFTSVs based on phylogenetic and molecular selection pressure analyses. By employing a time-scaled Bayesian inference method, we found the geographical heterogeneity of dominant SFTSV genotypes in China, Japan, and South Korea around several centuries before and locally spread by tick-born spillover with infrequent long-distance transmission. Purifying selection predominated the molecular evolution of SFTSVs with limited gene reassortment and fixed substitution, but almost all three gene segments appeared to harbor at least one amino acid residue under positive selection. Specifically, the nonstructural protein and glycoprotein (Gn/Gc) genes were preferential selective targets, and the Gn region retained the highest number of positively selected residues.Conclusion/significanceHere, the large-scale genomic analyses of SFTSVs improved prior knowledge of how this virus emerged and evolved in China, Japan, and South Korea. Our results highlight the importance of SFTSV surveillance in both human and non-human reservoirs at the molecular level to fight against fatal human infection with the virus.
- Published
- 2023
- Full Text
- View/download PDF
8. Molecular evolution and targeted recombination of SARS-CoV-2 in South Korea
- Author
-
Atanas V. Demirev, Kyuyoung Lee, Joon-Yong Bae, Heedo Park, Sejik Park, Hyunbeen Kim, Jungmin Lee, Junhyung Cho, Jeong-Sun Yang, Kyung-Chang Kim, Joo-Yeon Lee, Kisoon Kim, Philippe Lemey, Man-Seong Park, and Jin Il Kim
- Subjects
Virology ,Phylogenetics ,Science - Abstract
Summary: SARS-CoV-2 variants have continuously emerged globally, including in South Korea. To characterize the molecular evolution of SARS-CoV-2 in South Korea, we performed phylogenetic and genomic recombination analyses using more than 12,000 complete genome sequences collected until October 2022. The variants in South Korea originated from globally identified variants of concern and harbored genetic clade-common and clade-specific amino acid mutations mainly around the N-terminal domain (NTD) or receptor binding domain (RBD) in the spike protein. Several point mutation residues in key antigenic sites were under positive selection persistently with changing genetic clades of SARS-CoV-2. Furthermore, we detected 17 potential genomic recombinants and 76.4% (13/17) retained the mosaic NTD or RBD genome. Our results suggest that point mutations and genomic recombination in the spike contributed to the molecular evolution of SARS-CoV-2 in South Korea, which will form an integral part of global prevention and control measures against SARS-CoV-2.
- Published
- 2023
- Full Text
- View/download PDF
9. Kinetics of neutralizing antibodies against SARS-CoV-2 infection according to sex, age, and disease severity
- Author
-
Yoonjung Kim, Joon-Yong Bae, Kitae Kwon, Hyun-Ha Chang, Won Kee Lee, Heedo Park, Jeonghun Kim, Isaac Choi, Man-Seong Park, and Shin-Woo Kim
- Subjects
Medicine ,Science - Abstract
Abstract Knowledge of the factors affecting the difference in kinetics and longevity of the neutralizing antibody (nAb) response to SARS-CoV-2 is necessary to properly prioritize vaccination. In the present study, from March to December 2020, of the 143 patients who recovered from COVID-19, 87 underwent study visits scheduled every 3 months. Patient demographics and blood samples were collected followed by a plaque reduction neutralization test to analyze nAb titers. A linear mixed model was used to compare the effects of sex, age, and disease severity over time. Results demonstrated a gradual reduction in nAb titers over time with a significant decrease from 6 to 9 months post-COVID-19 infection (p
- Published
- 2022
- Full Text
- View/download PDF
10. Laboratory information management system for COVID-19 non-clinical efficacy trial data
- Author
-
Suhyeon Yoon, Hyuna Noh, Heejin Jin, Sungyoung Lee, Soyul Han, Sung-Hee Kim, Jiseon Kim, Jung Seon Seo, Jeong Jin Kim, In Ho Park, Jooyeon Oh, Joon-Yong Bae, Gee Eun Lee, Sun-Je Woo, Sun-Min Seo, Na-Won Kim, Youn Woo Lee, Hui Jeong Jang, Seung-Min Hong, Se-Hee An, Kwang-Soo Lyoo, Minjoo Yeom, Hanbyeul Lee, Bud Jung, Sun-Woo Yoon, Jung-Ah Kang, Sang-Hyuk Seok, Yu Jin Lee, Seo Yeon Kim, Young Been Kim, Ji-Yeon Hwang, Dain On, Soo-Yeon Lim, Sol Pin Kim, Ji Yun Jang, Ho Lee, Kyoungmi Kim, Hyo-Jung Lee, Hong Bin Kim, Jun Won Park, Dae Gwin Jeong, Daesub Song, Kang-Seuk Choi, Ho-Young Lee, Yang-Kyu Choi, Jung-ah Choi, Manki Song, Man-Seong Park, Jun-Young Seo, Ki Taek Nam, Jeon-Soo Shin, Sungho Won, Jun-Won Yun, and Je Kyung Seong
- Subjects
SARS-CoV-2 ,COVID-19 ,Non-clinical ,Laboratory information management system ,Data ,Medicine (General) ,R5-920 ,Biology (General) ,QH301-705.5 - Abstract
Abstract Background As the number of large-scale studies involving multiple organizations producing data has steadily increased, an integrated system for a common interoperable format is needed. In response to the coronavirus disease 2019 (COVID-19) pandemic, a number of global efforts are underway to develop vaccines and therapeutics. We are therefore observing an explosion in the proliferation of COVID-19 data, and interoperability is highly requested in multiple institutions participating simultaneously in COVID-19 pandemic research. Results In this study, a laboratory information management system (LIMS) approach has been adopted to systemically manage various COVID-19 non-clinical trial data, including mortality, clinical signs, body weight, body temperature, organ weights, viral titer (viral replication and viral RNA), and multiorgan histopathology, from multiple institutions based on a web interface. The main aim of the implemented system is to integrate, standardize, and organize data collected from laboratories in multiple institutes for COVID-19 non-clinical efficacy testings. Six animal biosafety level 3 institutions proved the feasibility of our system. Substantial benefits were shown by maximizing collaborative high-quality non-clinical research. Conclusions This LIMS platform can be used for future outbreaks, leading to accelerated medical product development through the systematic management of extensive data from non-clinical animal studies.
- Published
- 2022
- Full Text
- View/download PDF
11. Daily, self-test rapid antigen test to assess SARS-CoV-2 viability in de-isolation of patients with COVID-19
- Author
-
Seongman Bae, Heedo Park, Ji Yeun Kim, Sunghee Park, So Yun Lim, Joon-Yong Bae, Jeonghun Kim, Jiwon Jung, Min Jae Kim, Yong Pil Chong, Sang-Oh Lee, Sang-Ho Choi, Yang Soo Kim, Man-Seong Park, and Sung-Han Kim
- Subjects
COVID-19 ,rapid antigen test ,isolation ,de-isolation ,cell culture ,Medicine (General) ,R5-920 - Abstract
BackgroundIsolation of COVID-19 patients is a crucial infection control measure to prevent further SARS-CoV-2 transmission, but determining an appropriate timing to end the COVID-19 isolation is a challenging. We evaluated the performance of the self-test rapid antigen test (RAT) as a potential proxy to terminate the isolation of COVID-19 patients.Materials and methodsSymptomatic COVID-19 patients were enrolled who were admitted to a regional community treatment center (CTC) in Seoul (South Korea). Self-test RAT and the collection of saliva samples were performed by the patients, on a daily basis, until patient discharge. Cell culture and subgenomic RNA detection were performed on saliva samples.ResultsA total of 138 pairs of saliva samples and corresponding RAT results were collected from 34 COVID-19 patients. Positivity of RAT and cell culture was 27% (37/138) and 12% (16/138), respectively. Of the 16 culture-positive saliva samples, seven (43.8%) corresponding RAT results were positive. Using cell culture as the reference standard, the overall percent agreement, percent positive agreement, and percent negative agreement of RAT were 71% (95% CI, 63–78), 26% (95% CI, 12–42), and 82% (95% CI, 76–87), respectively. The sensitivity, specificity, positive predictive value, and negative predictive value of the RAT for predicting culture results were 44% (95% CI, 20–70), 75% (95% CI, 66–82), 18% (95% CI, 8–34), and 91% (95% CI, 84–96), respectively.ConclusionAbout half of the patients who were SARS-CoV-2 positive based upon cell culture results gave negative RAT results. However, the remaining positive culture cases were detected by RAT, and RAT showed relatively high negative predictive value for viable viral shedding.
- Published
- 2022
- Full Text
- View/download PDF
12. Comparison of vaccination efficacy using live or ultraviolet-inactivated influenza viruses introduced by different routes in a mouse model
- Author
-
Kyeongbin Baek, Sony Maharjan, Madhav Akauliya, Bikash Thapa, Dongbum Kim, Jinsoo Kim, Minyoung Kim, Mijeong Kang, Suyeon Kim, Joon-Yong Bae, Keun-Wook Lee, Man-Seong Park, Younghee Lee, and Hyung-Joo Kwon
- Subjects
Medicine ,Science - Abstract
Influenza is a major cause of highly contagious respiratory illness resulting in high mortality and morbidity worldwide. Annual vaccination is an effective way to prevent infection and complication from constantly mutating influenza strains. Vaccination utilizes preemptive inoculation with live virus, live attenuated virus, inactivated virus, or virus segments for optimal immune activation. The route of administration also affects the efficacy of the vaccination. Here, we evaluated the effects of inoculation with ultraviolet (UV)-inactivated or live influenza A virus strains and compared their effectiveness and cross protection when intraperitoneal and intramuscular routes of administration were used in mice. Intramuscular or intraperitoneal inoculation with UV-inactivated Influenza A/WSN/1933 provided some protection against intranasal challenge with a lethal dose of live Influenza A/WSN/1933 but only when a high dose of the virus was used in the inoculation. By contrast, inoculation with a low dose of live virus via either route provided complete protection against the same intranasal challenge. Intraperitoneal inoculation with live or UV-inactivated Influenza A/Philippines/2/1982 and intramuscular inoculation with UV-inactivated Influenza A/Philippines/2/1982 failed to produce cross-reactive antibodies against Influenza A/WSN/1933. Intramuscular inoculation with live Influenza A/Philippines/2/1982 induced small amounts of cross-reactive antibodies but could not suppress the cytokine storm produced upon intranasal challenge with Influenza A/WSN/1993. None of the tested inoculation conditions provided observable cross protection against intranasal challenge with a different influenza strain. Taken together, vaccination efficacy was affected by the state and dose of the vaccine virus and the route of administration. These results provide practical data for the development of effective vaccines against influenza virus.
- Published
- 2022
13. Serological Evidence of Severe Fever with Thrombocytopenia Syndrome Virus and IgM Positivity Were Identified in Healthy Residents in Vietnam
- Author
-
Xuan Chuong Tran, Sung Hye Kim, Jeong-Eun Lee, So-Hee Kim, Su Yeon Kang, Nguyen D. Binh, Pham V. Duc, Phan T. K. Phuong, Nguyen T. P. Thao, Wonwoo Lee, Joon-Yong Bae, Man-Seong Park, Misun Kim, Jeong Rae Yoo, Sang Taek Heo, Kyeong Ho An, Jung Mogg Kim, Nam-Hyuk Cho, Sun-Ho Kee, and Keun Hwa Lee
- Subjects
severe fever with thrombocytopenia syndrome virus (SFTSV) ,serological evidence ,IgM positivity ,healthy residents ,Vietnam ,Microbiology ,QR1-502 - Abstract
Severe fever with thrombocytopenia syndrome (SFTS), an emerging tick-borne viral disease, is prevalent in East Asia and has also been reported in Southeast Asia since 2019. SFTS patients in Vietnam were first reported in 2019. However, the seroprevalence of severe fever with thrombocytopenia syndrome virus (SFTSV) in Vietnam has not been reported. To investigate the seroprevalence of SFTSV in Vietnam, we collected serum samples from 714 healthy residents in Thua Thien Hue and Quang Nam Province, Vietnam, and the seroprevalence of SFTSV was assessed using immunofluorescence antibody assay (IFA), Enzyme-Linked Immunosorbent Assays (ELISAs) and the 50% focus reduction neutralization test (FRNT50) assay. The seroprevalence of anti-SFTSV IgM or IgG was observed to be 3.64% (26/714), high IgM positivity was >80 (0.28%, 2/714) and the titer of neutralizing antibodies against SFTSV ranged from 15.5 to 55.9. In Pakistan, SFTSV infection confirmed using a microneutralization test (MNT) assay (prevalence is 2.5%) and ELISAs showed a high seroprevalence (46.7%) of SFTSV. Hence, the seroprevalence rate in Vietnam is similar to that in Pakistan and the number of SFTS patients could increase in Vietnam.
- Published
- 2022
- Full Text
- View/download PDF
14. Comparison of the clinical and virological characteristics of SARS-CoV-2 Omicron BA.1/BA.2 and omicron BA.5 variants: A prospective cohort study
- Author
-
Sung-Woon Kang, Heedo Park, Ji Yeun Kim, So Yun Lim, Sohyun Lee, Joon-Yong Bae, Jeonghun Kim, Euijin Chang, Seongman Bae, Jiwon Jung, Min Jae Kim, Yong Pil Chong, Sang-Oh Lee, Sang-Ho Choi, Yang Soo Kim, Man-Seong Park, and Sung-Han Kim
- Subjects
Microbiology (medical) ,Infectious Diseases - Published
- 2023
15. Phylodynamics and Molecular Mutations of the Hemagglutinin Affecting Global Transmission and Host Adaptation of H5Nx Viruses
- Author
-
Atanas V. Demirev, Heedo Park, Kyuyoung Lee, Sejik Park, Joon-Yong Bae, Man-Seong Park, and Jin Il Kim
- Subjects
Article Subject ,General Veterinary ,General Immunology and Microbiology ,General Medicine - Abstract
Highly pathogenic avian influenza (HPAI) H5 viruses have circulated globally causing incidental human infection with a substantial pandemic threat. The present study investigated the molecular evolution and phylodynamics of hemagglutinin (HA) in avian and human-isolated H5Nx viruses globally circulating since 2000. We investigated the dynamics of amino acid substitution in the HA sequences of avian and human H5Nx viruses and performed a phylogenetic analysis. Our study found that the H5Nx lineages dominantly expanded since 2000 and diverged into multiple sublineages with unique genetic mutations. P185S mutation in HA became a molecular characteristic of dominant H5Nx viruses throughout clades 2.3.4.1 to 2.3.4.4 (2.3.4.1–4). The key mutations, ΔE130 and I155T, and potential N-linked glycosylation at residues 128, 144, and 159 in the HA gene of human-isolated viruses possibly contributed to both the individual and population levels of the H5 evolution and the host adaptation. Our analysis detected heterogeneity in amino acid sites under positive selection in the HA gene of clades 2.3.4.1–4. Accumulated mutations in the HA protein may potentially affect not only the genetic and antigenic diversity of HPAI H5Nx viruses but also increase the functional compatibility with NA subtypes. Given the global spread and incessantly occurring HA mutations of H5Nx viruses, our results emphasize the importance of early identification of HA mutations as well as the need for a comprehensive assessment of H5Nx variants in terms of pandemic preparedness.
- Published
- 2023
16. Comparison of culture-competent virus shedding duration of SARS-CoV-2 Omicron variant in regard to vaccination status: A prospective cohort study
- Author
-
Sung-Woon Kang, Heedo Park, Ji Yeun Kim, Joon-Yong Bae, Man-Seong Park, and Sung-Han Kim
- Subjects
Infectious Diseases ,General Veterinary ,General Immunology and Microbiology ,Public Health, Environmental and Occupational Health ,Molecular Medicine - Published
- 2023
17. Glycosylation generates an efficacious and immunogenic vaccine against H7N9 influenza virus.
- Author
-
Jin Il Kim, Sehee Park, Joon-Yong Bae, Sunmi Lee, Jeonghun Kim, Gayeong Kim, Kirim Yoo, Jun Heo, Yong Seok Kim, Jae Soo Shin, Mee Sook Park, and Man-Seong Park
- Subjects
Biology (General) ,QH301-705.5 - Abstract
Zoonotic avian influenza viruses pose severe health threats to humans. Of several viral subtypes reported, the low pathogenic avian influenza H7N9 virus has since February 2013 caused more than 1,500 cases of human infection with an almost 40% case-fatality rate. Vaccination of poultry appears to reduce human infections. However, the emergence of highly pathogenic strains has increased concerns about H7N9 pandemics. To develop an efficacious H7N9 human vaccine, we designed vaccine viruses by changing the patterns of N-linked glycosylation (NLG) on the viral hemagglutinin (HA) protein based on evolutionary patterns of H7 HA NLG changes. Notably, a virus in which 2 NLG modifications were added to HA showed higher growth rates in cell culture and elicited more cross-reactive antibodies than did other vaccine viruses with no change in the viral antigenicity. Developed into an inactivated vaccine formulation, the vaccine virus with 2 HA NLG additions exhibited much better protective efficacy against lethal viral challenge in mice than did a vaccine candidate with wild-type (WT) HA by reducing viral replication in the lungs. In a ferret model, the 2 NLG-added vaccine viruses also induced hemagglutination-inhibiting antibodies and significantly suppressed viral replication in the upper and lower respiratory tracts compared with the WT HA vaccines. In a mode of action study, the HA NLG modification appeared to increase HA protein contents incorporated into viral particles, which would be successfully translated to improve vaccine efficacy. These results suggest the strong potential of HA NLG modifications in designing avian influenza vaccines.
- Published
- 2020
- Full Text
- View/download PDF
18. Temporal Transcriptome Analysis of SARS-CoV-2-Infected Lung and Spleen in Human ACE2-Transgenic Mice
- Author
-
Jung Ah Kim, Sung-Hee Kim, Jung Seon Seo, Hyuna Noh, Haengdueng Jeong, Jiseon Kim, Donghun Jeon, Jeong Jin Kim, Dain On, Suhyeon Yoon, Sang Gyu Lee, Youn Woo Lee, Hui Jeong Jang, In Ho Park, Jooyeon Oh, Sang-Hyuk Seok, Yu Jin Lee, Seung-Min Hong, Se-Hee An, Joon-Yong Bae, Jung-ah Choi, Seo Yeon Kim, Young Been Kim, Ji-Yeon Hwang, Hyo-Jung Lee, Hong Bin Kim, Dae Gwin Jeong, Daesub Song, Manki Song, Man-Seong Park, Kang-Seuk Choi, Jun Won Park, Jun-Won Yun, Jeon-Soo Shin, Ho-Young Lee, Jun-Young Seo, Ki Taek Nam, Heon Yung Gee, and Je Kyung Seong
- Subjects
Cell Biology ,General Medicine ,Molecular Biology - Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a highly transmissible and potentially fatal virus. So far, most comprehensive analyses encompassing clinical and transcriptional manifestation have concentrated on the lungs. Here, we confirmed evident signs of viral infection in the lungs and spleen of SARS-CoV-2-infected K18-hACE2 mice, which replicate the phenotype and infection symptoms in hospitalized humans. Seven days post viral detection in organs, infected mice showed decreased vital signs, leading to death. Bronchopneumonia due to infiltration of leukocytes in the lungs and reduction in the spleen lymphocyte region were observed. Transcriptome profiling implicated the meticulous regulation of distress and recovery from cytokine-mediated immunity by distinct immune cell types in a time-dependent manner. In lungs, the chemokine-driven response to viral invasion was highly elevated at 2 days post infection (dpi). In late infection, diseased lungs, post the innate immune process, showed recovery signs. The spleen established an even more immediate line of defense than the lungs, and the cytokine expression profile dropped at 7 dpi. At 5 dpi, spleen samples diverged into two distinct groups with different transcriptome profile and pathophysiology. Inhibition of consecutive host cell viral entry and massive immunoglobulin production and proteolysis inhibition seemed that one group endeavored to survive, while the other group struggled with developmental regeneration against consistent viral intrusion through the replication cycle. Our results may contribute to improved understanding of the longitudinal response to viral infection and development of potential therapeutics for hospitalized patients affected by SARS-CoV-2.
- Published
- 2022
19. Performance Evaluation of the BZ COVID-19 Neutralizing Antibody Test for the Culture-Free and Rapid Detection of SARS-CoV-2 Neutralizing Antibodies
- Author
-
Bo Kyeung Jung, Jung Yoon, Joon-Yong Bae, Jeonghun Kim, Man-Seong Park, Suk Yong Lee, and Chae Seung Lim
- Subjects
SARS-CoV-2 ,COVID-19 ,neutralizing antibodies ,RDT ,ELISA ,Medicine (General) ,R5-920 - Abstract
Rapid and accurate measurement of SARS-CoV-2 neutralizing antibodies (nAbs) can aid in understanding the development of immunity against COVID-19. This study evaluated the diagnostic performance of a rapid SARS-CoV-2 nAb detection test called the BZ COVID-19 nAb test BZ-nAb (BZ-nAb; BioZentech). Using the 90% plaque-reduction neutralization test (PRNT-90) as a reference, 104 serum specimens collected from COVID-19-positive and -negative patients were grouped into 40 PRNT-90-positive and 64 PRNT-90-negative specimens. The performance of the BZ-nAb was compared with that of the cPass surrogate virus neutralization test (cPass sVNT; Genscript). The BZ-nAb showed a sensitivity ranging from 92.5%–95.0% and specificity ranging from 96.9%–100%, whereas cPass sVNT showed a sensitivity of 100% (95% confidence interval (CI) 90.5%–100%) and specificity of 98.4% (95% CI, 91.6%–100%). The dilution factor obtained with PRNT-90 showed a stronger correlation with the percent inhibition of cPass sVNT (r = 0.8660, p < 0.001) compared with the test and control line ratio (T/C ratio) of the BZ-nAb (r = −0.7089, p < 0.001). An almost perfect agreement was seen between the BZ-nAb and cPass sVNT results, with a strong negative correlation between the BZ-nAb T/C ratio and cPass sVNT percent inhibition (r = −0.8022, p < 0.001). In conclusion, the diagnostic performance of the BZ-nAb was comparable to that of the cPass sVNT, although the BZ-nAb had a slightly lower sensitivity.
- Published
- 2021
- Full Text
- View/download PDF
20. Viable SARS-CoV-2 shedding under remdesivir and dexamethasone treatment
- Author
-
Jin Gu Yoon, Jin Sae Yoo, Jungmin Lee, Hak-Jun Hyun, Hye Seong, Ji Yun Noh, Hee Jin Cheong, Woo Joo Kim, Young Rong Kim, Jung Yeon Heo, Joon-Yong Bae, Chunguang Cui, Sohyun Lee, Man-Seong Park, and Joon Young Song
- Subjects
Microbiology (medical) ,Alanine ,Infectious Diseases ,SARS-CoV-2 ,Humans ,Antiviral Agents ,Adenosine Monophosphate ,Dexamethasone ,COVID-19 Drug Treatment - Published
- 2022
21. The Immune Correlates of Orthohantavirus Vaccine
- Author
-
Joon-Yong Bae, Jin Il Kim, Mee Sook Park, Gee Eun Lee, Heedo Park, Ki-Joon Song, and Man-Seong Park
- Subjects
antigenicity ,glycoprotein ,orthohantavirus ,pandemic ,vaccine ,Medicine - Abstract
Zoonotic transmission of orthohantaviruses from rodent reservoirs to humans has been the cause of severe fatalities. Human infections are reported worldwide, but vaccines have been approved only in China and Korea. Orthohantavirus vaccine development has been pursued with no sense of urgency due to the relative paucity of cases in countries outside China and Korea. However, the orthohantaviruses continuously evolve in hosts and thus the current vaccine may not work as well against some variants. Therefore, a more effective vaccine should be prepared against the orthohantaviruses. In this review, we discuss the issues caused by the orthohantavirus vaccine. Given the pros and cons of the orthohantavirus vaccine, we suggest strategies for the development of better vaccines in terms of pandemic preparedness.
- Published
- 2021
- Full Text
- View/download PDF
22. Robust and durable poly(aryl-co-aryl piperidinium) reinforced membranes for alkaline membrane fuel cells
- Author
-
Chuan Hu, Jong Hyeong Park, Hae Min Kim, Ho Hyun Wang, Joon Yong Bae, Mei-Ling Liu, Na Yoon Kang, Kyoung-seok Yoon, Chang-dae Park, Nanjun Chen, and Young Moo Lee
- Subjects
Renewable Energy, Sustainability and the Environment ,General Materials Science ,General Chemistry - Abstract
Polyethylene reinforced poly(aryl-co-aryl piperidinium) based membranes possess outstanding mechanical properties (tensile strength: 114 MPa, elongation at break: 159%) along with a fuel cell performance of 1.75 W cm−2 at 80 °C.
- Published
- 2022
23. Clustering and multiple-spreading events of nosocomial severe acute respiratory syndrome coronavirus 2 infection
- Author
-
Mi-Na Kim, So Yun Lim, Young-Ju Lim, Joon-Yong Bae, Man-Seong Park, Jiwon Jung, Sung-Han Kim, Heungsup Sung, Sun Hee Kwak, Seongman Bae, Min Jee Hong, Jungmin Lee, and Eun Ok Kim
- Subjects
Microbiology (medical) ,2019-20 coronavirus outbreak ,medicine.medical_specialty ,Coronavirus disease 2019 (COVID-19) ,Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) ,SARS-CoV-2, severe acute respiratory syndrome coronavirus 2 ,Article ,Internal medicine ,SSE, super-spreading event ,medicine ,Cluster Analysis ,Humans ,Symptom onset ,WGS, whole-genome sequencing ,IQR, interquartile range ,COVID-19, coronavirus disease 2019 ,Cross Infection ,HCW, healthcare worker ,SARS-CoV-2 ,CCTV, closed-circuit television ,Transmission (medicine) ,business.industry ,MSE, multiple-spreading event ,transmission ,COVID-19 ,General Medicine ,Infectious Diseases ,Healthcare settings ,Contact Tracing ,SNP, single-nucleotide polymorphism ,business ,PPE, personal protective equipment ,Contact tracing ,Case identification - Abstract
Summary Background There is growing evidence that super-spreading events (SSEs) and multiple-spreading events (MSEs) are a characteristic feature of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. However, data regarding the possibility of SSEs or MSEs in healthcare settings are limited. Methods This study was performed at a tertiary-care hospital in Korea. We analysed the nosocomial COVID-19 cases that occurred in healthcare workers and inpatients and their caregivers between January and 20th December 2020. Cases with two to four secondary cases were defined as MSEs and those with five or more secondary cases as SSEs. Findings We identified 21 nosocomial events (single-case events, N = 12 (57%); MSE + SSE, N = 9 (43%)) involving 65 individuals with COVID-19. Of these 65 individuals, 21 (32%) were infectors. The infectors tended to have a longer duration between symptom onset and diagnostic confirmation than did the non-infectors (median two days vs zero days, P=0.08). Importantly, 12 (18%) individuals were responsible for MSEs and one (2%) for an SSE, which collectively generated 35 (54%) secondary cases. Conclusion In a hospital with thorough infection-control measures, approximately 70% of the nosocomial cases of COVID-19 did not generate secondary cases, and one-fifth of the infectors were responsible for SSEs and MSEs, which accounted for approximately half of the total cases. Early case identification, isolation, and extensive contact tracing are important for the prevention of transmission and SSEs.
- Published
- 2021
24. Establishment of multicenter COVID-19 therapeutics preclinical test system in Republic of Korea
- Author
-
Hyuna Noh, Suhyeon Yoon, Sung-Hee Kim, Jiseon Kim, Jung Seon Seo, Jeong Jin Kim, In Ho Park, Jooyeon Oh, Joon-Yong Bae, Gee Eun Lee, Sun-Je Woo, Sun-Min Seo, Na-Won Kim, Youn Woo Lee, Hui Jeong Jang, Seung-Min Hong, Se-Hee An, Kwang-Soo Lyoo, Minjoo Yeom, Hanbyeul Lee, Bud Jung, Sun-Woo Yoon, Jung-Ah Kang, Sang-Hyuk Seok, Yu Jin Lee, Seo Yeon Kim, Young Been Kim, Ji-Yeon Hwang, Dain On, Soo-Yeon Lim, Sol Pin Kim, Ji Yun Jang, Ho Lee, Kyoungmi Kim, Hyo-Jung Lee, Hong Bin Kim, Sun Bean Kim, Jun Won Park, Dae Gwin Jeong, Daesub Song, Kang-Seuk Choi, Ho-Young Lee, Yang-Kyu Choi, Jung-ah Choi, Manki Song, Man-Seong Park, Jun-Young Seo, Jeon-Soo Shin, Jun-Won Yun, Ki Taek Nam, and Je Kyung Seong
- Subjects
Pulmonary and Respiratory Medicine ,Biochemistry (medical) ,Pharmacology (medical) - Published
- 2023
25. Nosocomial Outbreak of COVID-19 in a Hematologic Ward
- Author
-
Jiwon Jung, Ji Yeun Kim, Jungmin Lee, Seongman Bae, Man Seong Park, Seongmin Jo, Joon Yong Bae, Young Ju Lim, Sun Hee Kwak, Hye Hee Cha, Minki Sung, Eun Ok Kim, Changmin Kang, Sung-Han Kim, and Min Jee Hong
- Subjects
2019-20 coronavirus outbreak ,Hematologic malignancy ,Coronavirus disease 2019 (COVID-19) ,Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) ,Multi-patient room ,Airborne transmission ,03 medical and health sciences ,0302 clinical medicine ,medicine ,Pharmacology (medical) ,030212 general & internal medicine ,Close contact ,0303 health sciences ,Nosocomial outbreak ,030306 microbiology ,business.industry ,SARS-CoV-2 ,COVID-19 ,medicine.disease ,Infectious Diseases ,Original Article ,Medical emergency ,business ,Contact tracing - Abstract
BACKGROUND: Coronavirus disease 2019 (COVID-19) outbreaks occur in hospitals in many parts of the world. In hospital settings, the possibility of airborne transmission needs to be investigated thoroughly. MATERIALS AND METHODS: There was a nosocomial outbreak of COVID-19 in a hematologic ward in a tertiary hospital, Seoul, Korea. We found 11 patients and guardians with COVID-19 through vigorous contact tracing and closed-circuit television monitoring. We found one patient who probably had acquired COVID-19 through airborne-transmission. We performed airflow investigation with simulation software, whole-genome sequencing of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). RESULTS: Of the nine individuals with COVID-19 who had been in the hematologic ward, six stayed in one multi-patient room (Room 36), and other three stayed in different rooms (Room 1, 34, 35). Guardian in room 35 was close contact to cases in room 36, and patient in room 34 used the shared bathroom for teeth brushing 40 minutes after index used. Airflow simulation revealed that air was spread from the bathroom to the adjacent room 1 while patient in room 1 did not used the shared bathroom. Airflow was associated with poor ventilation in shared bathroom due to dysfunctioning air-exhaust, grill on the door of shared bathroom and the unintended negative pressure of adjacent room. CONCLUSION: Transmission of SARS-CoV-2 in the hematologic ward occurred rapidly in the multi-patient room and shared bathroom settings. In addition, there was a case of possible airborne transmission due to unexpected airflow.
- Published
- 2021
26. Neutralizing Antibody Responses to SARS-CoV-2 in Korean Patients Who Have Recovered from COVID-19
- Author
-
Soyoon Hwang, Shin Woo Kim, Hyun-Ha Chang, Man Seong Park, Yoonjung Kim, Won Kee Lee, Ki Tae Kwon, Sohyun Bae, Joon Yong Bae, Gee Eun Lee, and Chunguang Cui
- Subjects
myalgia ,Adult ,medicine.medical_specialty ,Nausea ,030204 cardiovascular system & hematology ,Logistic regression ,Antibodies, Viral ,Gastroenterology ,03 medical and health sciences ,0302 clinical medicine ,Plaque reduction neutralization test ,neutralization assay ,Internal medicine ,Republic of Korea ,medicine ,Humans ,neutralizing antibodies ,Neutralizing antibody ,biology ,business.industry ,SARS-CoV-2 ,COVID-19 ,General Medicine ,Middle Aged ,immunity ,Antibodies, Neutralizing ,Titer ,Infectious Diseases ,030220 oncology & carcinogenesis ,Vomiting ,biology.protein ,Original Article ,medicine.symptom ,Antibody ,business - Abstract
PURPOSE: Neutralizing antibodies (NAbs) have been considered effective in preventing and treating viral infections. However, until now, the duration and clinical implications of antibody-mediated nature immunity in Koreans have remained unknown. Therefore, we examined NAbs levels and clinical characteristics in recovered coronavirus disease 2019 (COVID-19) patients. MATERIALS AND METHODS: Blood samples were collected from 143 adult patients who had been diagnosed with and had recovered from COVID-19 from February to March in 2020 at a tertiary-care university-affiliated hospital in Daegu, Korea. A plaque reduction neutralization test was conducted to analyze NAb titers. Individualized questionnaires were used to identify patient clinical information. RESULTS: The median number of days from symptom onset to the blood collection date was 109.0 (104.0; 115.0). The NAb titers ranged from 10 to 2560. The median NAb titer value was 40. Of the 143 patients, 68 (47.6%) patients had NAb titers ≥80, and 31 (21.7%) patients had NAb titers ≥160. The higher the age or disease severity, the higher the NAb titer. In univariate logistic regression, statistically significant predictors of high NAb titers (≥80) were age, myalgia, nausea or vomiting, dyspnea, and disease severity (p
- Published
- 2021
27. Phylogenetic relationships of the HA and NA genes between vaccine and seasonal influenza A(H3N2) strains in Korea.
- Author
-
Jin Il Kim, Ilseob Lee, Sehee Park, Joon-Yong Bae, Kirim Yoo, Hee Jin Cheong, Ji Yun Noh, Kyung Wook Hong, Philippe Lemey, Bram Vrancken, Juwon Kim, Misun Nam, Soo-Hyeon Yun, Woo In Cho, Joon Young Song, Woo Joo Kim, Mee Sook Park, Jin-Won Song, Sun-Ho Kee, Ki-Joon Song, and Man-Seong Park
- Subjects
Medicine ,Science - Abstract
Seasonal influenza is caused by two influenza A subtype (H1N1 and H3N2) and two influenza B lineage (Victoria and Yamagata) viruses. Of these antigenically distinct viruses, the H3N2 virus was consistently detected in substantial proportions in Korea during the 2010/11-2013/14 seasons when compared to the other viruses and appeared responsible for the influenza-like illness rate peak during the first half of the 2011/12 season. To further scrutinize possible causes for this, we investigated the evolutionary and serological relationships between the vaccine and Korean H3N2 strains during the 2011/12 season for the main antigenic determinants of influenza viruses, the hemagglutinin (HA) and neuraminidase (NA) genes. In the 2011/12 season, when the number of H3N2 cases peaked, the majority of the Korean strains did not belong to the HA clade of A/Perth/16/2009 vaccine, and no Korean strains were of this lineage in the NA segment. In a serological assay, post-vaccinated human sera exhibited much reduced hemagglutination inhibition antibody titers against the non-vaccine clade Korean H3N2 strains. Moreover, Korean strains harbored several amino acid differences in the HA antigenic sites and in the NA with respect to vaccine lineages during this season. Of these, the HA antigenic site C residues 45 and 261 and the NA residue 81 appeared to be the signatures of positive selection. In subsequent seasons, when H3N2 cases were lower, the HA and NA genes of vaccine and Korean strains were more phylogenetically related to each other. Combined, our results provide indirect support for using phylogenetic clustering patterns of the HA and possibly also the NA genes in the selection of vaccine viruses and the assessment of vaccine effectiveness.
- Published
- 2017
- Full Text
- View/download PDF
28. Clinical scoring system to predict viable viral shedding in patients with COVID-19
- Author
-
Sung Woon Kang, Heedo Park, Ji Yeun Kim, Sunghee Park, So Yun Lim, Sohyun Lee, Joon-Yong Bae, Jeonghun Kim, Seongman Bae, Jiwon Jung, Min Jae Kim, Yong Pil Chong, Sang-Oh Lee, Sang-Ho Choi, Yang Soo Kim, Sung-Cheol Yun, Man-Seong Park, and Sung-Han Kim
- Subjects
Adult ,Infectious Diseases ,COVID-19 Testing ,SARS-CoV-2 ,Virology ,Humans ,COVID-19 ,Viral Load ,United States ,Virus Shedding - Abstract
The Centers for Disease Control and Prevention (CDC) recommends 5-10 days of isolation for patients with COVID-19, depending on symptom duration and severity. However, in clinical practice, an individualized approach is required. We thus developed a clinical scoring system to predict viable viral shedding.We prospectively enrolled adult patients with SARS-CoV-2 infection admitted to a hospital or community isolation facility between February 2020 and January 2022. Daily dense respiratory samples were obtained, and genomic RNA viral load assessment and viral culture were performed. Clinical predictors of negative viral culture results were identified using survival analysis and multivariable analysis.Among 612 samples from 121 patients including 11 immunocompromised patients (5 organ transplant recipients, 5 with hematologic malignancy, and 1 receiving immunosuppressive agents) with varying severity, 154 (25%) revealed positive viral culture results. Multivariable analysis identified symptom onset day, viral copy number, disease severity, organ transplant recipient, and vaccination status as independent predictors of culture-negative rate. We developed a 4-factor predictive model based on viral copy number (-3 to 3 points), disease severity (1 point for moderate to critical disease), organ transplant recipient (2 points), and vaccination status (-2 points for fully vaccinated). Predicted culture-negative rates were calculated through the symptom onset day and the score of the day the sample was collected.Our clinical scoring system can provide the objective probability of a culture-negative state in a patient with COVID-19 and is potentially useful for implementing personalized de-isolation policies beyond the simple symptom-based isolation strategy.
- Published
- 2022
29. Multifactorial Traits of SARS-CoV-2 Cell Entry Related to Diverse Host Proteases and Proteins
- Author
-
Myungsoo Joo, Kisoon Kim, Jong Hyeon Seok, Joon Yong Bae, Jaehwan You, Man Seong Park, and Jin Il Kim
- Subjects
0301 basic medicine ,Proteases ,medicine.drug_class ,viruses ,Review ,Biology ,Bioinformatics ,Biochemistry ,Virus ,03 medical and health sciences ,0302 clinical medicine ,Viral entry ,Drug Discovery ,Pandemic ,Global health ,medicine ,Pharmacology ,SARS-CoV-2 ,Antiviral drugs ,Mechanism (biology) ,Cellular proteins ,Cell entry ,030104 developmental biology ,030220 oncology & carcinogenesis ,Emerging infectious disease ,Molecular Medicine ,Antiviral drug - Abstract
The most effective way to control newly emerging infectious disease, such as the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic, is to strengthen preventative or therapeutic public health strategies before the infection spreads worldwide. However, global health systems remain at the early stages in anticipating effective therapeutics or vaccines to combat the SARS-CoV-2 pandemic. While maintaining social distance is the most crucial metric to avoid spreading the virus, symptomatic therapy given to patients on the clinical manifestations helps save lives. The molecular properties of SARS-CoV-2 infection have been quickly elucidated, paving the way to therapeutics, vaccine development, and other medical interventions. Despite this progress, the detailed biomolecular mechanism of SARS-CoV-2 infection remains elusive. Given virus invasion of cells is a determining factor for virulence, understanding the viral entry process can be a mainstay in controlling newly emerged viruses. Since viral entry is mediated by selective cellular proteases or proteins associated with receptors, identification and functional analysis of these proteins could provide a way to disrupt virus propagation. This review comprehensively discusses cellular machinery necessary for SARS-CoV-2 infection. Understanding multifactorial traits of the virus entry will provide a substantial guide to facilitate antiviral drug development.
- Published
- 2021
30. Antiviral Efficacy of Pralatrexate against SARS-CoV-2
- Author
-
Juyoung Cho, Gee Eun Lee, Man Seong Park, Jin Il Kim, Jungmin Lee, Heedo Park, Joon Yong Bae, Kisoon Kim, and Jeonghun Kim
- Subjects
0301 basic medicine ,Coronavirus disease 2019 (COVID-19) ,Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) ,viruses ,Drug repurposing ,Review ,medicine.disease_cause ,Biochemistry ,03 medical and health sciences ,0302 clinical medicine ,Drug Discovery ,Medicine ,Antiviral ,Cytotoxicity ,Coronavirus ,Pharmacology ,business.industry ,SARS-CoV-2 ,Pralatrexate ,COVID-19 ,Virology ,Drug repositioning ,030104 developmental biology ,Viral replication ,Infectious disease (medical specialty) ,030220 oncology & carcinogenesis ,Molecular Medicine ,business ,medicine.drug - Abstract
Novel coronavirus (SARS-CoV-2) has caused more than 100 million confirmed cases of human infectious disease (COVID-19) since December 2019 to paralyze our global community. However, only limited access has been allowed to COVID-19 vaccines and antiviral treatment options. Here, we report the efficacy of the anticancer drug pralatrexate against SARS-CoV-2. In Vero and human lung epithelial Calu-3 cells, pralatrexate reduced viral RNA copies of SARS-CoV-2 without detectable cytotoxicity, and viral replication was successfully inhibited in a dose-dependent manner. In a time-to-addition assay, pralatrexate treatment at almost half a day after infection also exhibited inhibitory effects on the replication of SARS-CoV-2 in Calu-3 cells. Taken together, these results suggest the potential of pralatrexate as a drug repurposing COVID-19 remedy.
- Published
- 2021
31. Poly(Alkyl‐Terphenyl Piperidinium) Ionomers and Membranes with an Outstanding Alkaline‐Membrane Fuel‐Cell Performance of 2.58 W cm −2
- Author
-
Won Hee Lee, Joon Yong Bae, Hae Min Kim, Ho Hyun Wang, Chuan Hu, Nanjun Chen, Sun Pyo Kim, Young Moo Lee, and Jong Hyeong Park
- Subjects
anion exchange membranes ,Materials science ,peak power density ,fuel cells ,010402 general chemistry ,01 natural sciences ,Catalysis ,poly(alkyl terphenyl piperidinium) ,chemistry.chemical_compound ,Adsorption ,Terphenyl ,Ultimate tensile strength ,Copolymer ,anion exchange ionomers ,Research Articles ,Alkyl ,chemistry.chemical_classification ,010405 organic chemistry ,General Medicine ,General Chemistry ,Dynamic mechanical analysis ,0104 chemical sciences ,Membrane ,Chemical engineering ,chemistry ,Fuel Cells | Hot Paper ,Research Article - Abstract
Aryl‐ether‐free anion‐exchange ionomers (AEIs) and membranes (AEMs) have become an important benchmark to address the insufficient durability and power‐density issues associated with AEM fuel cells (AEMFCs). Here, we present aliphatic chain‐containing poly(diphenyl‐terphenyl piperidinium) (PDTP) copolymers to reduce the phenyl content and adsorption of AEIs and to increase the mechanical properties of AEMs. Specifically, PDTP AEMs possess excellent mechanical properties (storage modulus>1800 MPa, tensile strength>70 MPa), H2 fuel‐barrier properties (7.6 A cm−2 current density) and 1.38 W cm−2 at 80 °C in H2/O2 and H2/air, respectively, along with a specific power (PPD/catalyst loading) over 8 W mg−1, which is the highest record for Pt‐based AEMFCs so far., Poly(alkyl‐terphenyl piperidinium) membranes and ionomers display outstanding hydrogen‐barrier properties and mechanical properties as well as excellent hydroxide‐ion conductivity that results in an excellent power density of 2.58 W cm−2 and 1.38 W cm−2 at 80 °C in H2/O2 and H2/air, respectively, along with a new, outstanding specific power in alkaline‐exchange‐membrane fuel cells.
- Published
- 2021
32. Immunogenicity and safety of a modified three-dose priming and booster schedule for the Hantaan virus vaccine (Hantavax): A multi-center phase III clinical trial in healthy adults
- Author
-
Jong Woo Yun, Won Seok Choi, Dae Won Park, Heung Jeong Woo, Jacob Lee, Ji Yun Noh, Joon Yong Bae, Man Seong Park, Hye Won Jeong, Hee-Jin Cheong, Woo Joo Kim, and Joon Young Song
- Subjects
Adult ,medicine.medical_specialty ,Vaccination schedule ,030231 tropical medicine ,Immunization, Secondary ,Booster dose ,03 medical and health sciences ,Immunogenicity, Vaccine ,0302 clinical medicine ,Internal medicine ,medicine ,Humans ,030212 general & internal medicine ,Seroconversion ,Adverse effect ,Aged ,Booster (rocketry) ,General Veterinary ,General Immunology and Microbiology ,business.industry ,Immunogenicity ,Vaccination ,Public Health, Environmental and Occupational Health ,Antibodies, Neutralizing ,Hantaan virus ,Clinical trial ,Infectious Diseases ,Vaccines, Inactivated ,Molecular Medicine ,business - Abstract
Background Hemorrhagic fever with renal syndrome is a serious health problem in Eurasian countries. This study aimed to evaluate the immunogenicity and safety of formalin-inactivated Hantaan virus vaccine (Hantavax®) with a 3 + 1 vaccination schedule. Methods A phase III, multi-center clinical trial was conducted to evaluate the immunogenicity and safety of Hantavax® (three primary doses and a booster dose schedule at 0, 1, 2 and 13 months) among healthy adults. Immune responses were assessed using the plaque reduction neutralizing antibody test (PRNT) and immunofluorescent antibody assay (IFA). Systemic and local adverse events were assessed. Results A total of 320 healthy subjects aged ≥19 years were enrolled. Following three primary doses of Hantavax®, the seroconversion rate was 80.97% and 92.81% by PRNT and IFA, respectively. With booster administration, seropositive rates were 67.47% and 95.68% at one-month post-vaccination according to PRNT and IFA, respectively. Solicited local and systemic adverse events were reported in 30.50–42.81% and 16.67–33.75% during the three primary dose vaccination, while those were reported 36.57% and 21.36% after the booster doses. Both local and systemic adverse events did not increase with repeated vaccinations. Conclusion Hantavax® showed a high seroconversion rate after the three-dose priming, and additional dose administration with 11-month interval induced good booster effects. (ClinicalTrials.gov Identifier: NCT02553837).
- Published
- 2020
33. In Vitro Virucidal Effect of Povidone-Iodine Against SARS-CoV-2
- Author
-
Man Seong Park, Kyunghee Kwak, Kyeong Shin, Chunguang Cui, Woosung Hong, and Joon Yong Bae
- Subjects
Viral Plaque Assay ,business.industry ,Contact time ,viruses ,Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) ,media_common.quotation_subject ,Immunology ,Microbiology ,Virology ,In vitro ,Virus ,Titer ,Hygiene ,Vero cell ,Medicine ,business ,media_common - Abstract
As of September 2020, SARS-CoV-2 has infected over 30 million people worldwide, and the death toll has now risen to 950,000. Given that Povidone-iodine (PVP-I) had consistently been showing the virucidal efficacy against various types of viruses, such as SARS-CoV, MERS-CoV, and Ebola, we conducted this study to figure out the virucidal effect against SARS-CoV-2 by using a viral plaque assay. We performed Kill-Time assays to assess the viral inactivation of SARS-CoV-2 contaminants after the application of the PVP-I product (Betadine® Throat Spray, PVP-I 0.45%). This test consisted of clean and dirty conditions and was designed to check the viral titers at a contact time of 60 seconds, which were evaluated by plaque-reduction rates in Vero cells. This PVP-I product fully achieved ≥4 log10 reductions in viral titers under both clean and dirty conditions. This level of reduction, ≥4 log10 (99.99%), in viral titers presented to be effective in terms of virucidal efficacy, according to the European standards, EN14476. This study revealed the virucidal efficacy of Betadine® Throat Spray against SARS-CoV-2 virus. Given that the convenience and availability of this product, we think that it may contribute to inhibit viral infection and transmissibility as an active type of personal protective equipment (PPE) by managing the hygiene of patients and medical professionals.
- Published
- 2020
34. Preclinical study of influenza bivalent vaccine delivered with a two compartmental microneedle array
- Author
-
Gayeong Kim, Jee Hyun Park, Hye Rin Jeong, Seung Ki Baek, Man Seong Park, Joon Yong Bae, and Jung-Hwan Park
- Subjects
Single administration ,Single product ,Influenza vaccine ,Pharmaceutical Science ,02 engineering and technology ,Pharmacology ,Antibodies, Viral ,Neutralization ,Bivalent (genetics) ,Combination vaccines ,Mice ,03 medical and health sciences ,Influenza A Virus, H1N1 Subtype ,Influenza, Human ,Animals ,Vaccines, Combined ,Neutralizing antibody ,health care economics and organizations ,030304 developmental biology ,0303 health sciences ,biology ,Chemistry ,Vaccination ,Weight change ,021001 nanoscience & nanotechnology ,humanities ,Influenza Vaccines ,Needles ,biology.protein ,0210 nano-technology - Abstract
Multiple vaccines can be mixed into a single combination to be a single product. However, combination vaccines have problems of complexity. In this study, microneedles were utilized in a compartmental microneedle array (CMA) to deliver two influenza vaccine strains without mixing. In this study, the CMA had two compartments, and two rectangular structures were attached to each end of the array to enable integration of the compartments with the coating equipment. The coating solution, which contained influenza vaccines for B/Yamagata (B-Y) and B/Victoria (B-V), was filled into the two reservoirs of the container. The CMA was aligned with the container for dipping the first compartment of the array into the first reservoir and the second compartment into the second reservoir. The CMA containing B-Y and B-V separately was administered to mice, and weight change and survival were compared with other groups of mice administered (a) combination vaccines with microneedles, (b) two monovalent vaccines with microneedles, (c) intramuscularly with a combination vaccine, and (d) intramuscularly with two monovalent vaccines. Plaque reduction neutralization tests were also performed to compare the CMA group with the other groups. The CMA showed a relative standard error of less than 7% between samples in dose uniformity. It also showed comparable antibody-forming efficacy compared to other groups, especially by B/Yamagata virus challenge. The CMA mice group showed better survival and weight change than mice that received intramuscular (IM) injection of the combination vaccine. In the neutralizing antibody experiment, all microneedle groups showed a higher neutralizing antibody than the IM groups. Vaccines were administered without mixing by a single administration using a CMA, and the CMA showed comparable efficacy with IM administration of the combination vaccine. Multivalent vaccines can be delivered without mixing as a single product by using a CMA.
- Published
- 2020
35. Animal models for the risk assessment of viral pandemic potential
- Author
-
Mee Sook Park, Joon-Yong Bae, Jin Il Kim, and Man-Seong Park
- Subjects
0301 basic medicine ,Middle East respiratory syndrome coronavirus ,viruses ,030106 microbiology ,Review ,Biology ,medicine.disease_cause ,Virus ,Dengue fever ,03 medical and health sciences ,Zoonosis ,Animal model ,Pandemic ,medicine ,Pathogenicity ,Transmission ,lcsh:QH301-705.5 ,lcsh:R5-920 ,Transmission (medicine) ,medicine.disease ,Virology ,030104 developmental biology ,lcsh:Biology (General) ,Risk assessment ,lcsh:Medicine (General) - Abstract
Pandemics affect human lives severely and globally. Experience predicts that there will be a pandemic for sure although the time is unknown. When a viral epidemic breaks out, assessing its pandemic risk is an important part of the process that characterizes genomic property, viral pathogenicity, transmission in animal model, and so forth. In this review, we intend to figure out how a pandemic may occur by looking into the past influenza pandemic events. We discuss interpretations of the experimental evidences resulted from animal model studies and extend implications of viral pandemic potentials and ingredients to emerging viral epidemics. Focusing on the pandemic potential of viral infectious diseases, we suggest what should be assessed to prevent global catastrophes from influenza virus, Middle East respiratory syndrome coronavirus, dengue and Zika viruses.
- Published
- 2020
36. Elucidating the Role of Alkyl Chain in Poly(Aryl Piperidinium) Copolymers for Anion Exchange Membrane Fuel Cells
- Author
-
Chuan Hu, Jong Hyeong Park, Hae Min Kim, Joon Yong Bae, Na Yoon Kang, Nanjun Chen, and Young Moo Lee
- Subjects
History ,Polymers and Plastics ,Business and International Management ,Industrial and Manufacturing Engineering - Published
- 2022
37. Clinical Application of a Solid-Phase Assay for SARS-CoV-2 IgG to Predict a Neutralizing Antibody Titer
- Author
-
Yoonjung Kim, Joon-Yong Bae, Gee Lee, Heedo Park, Kitae Kwon, Hyun-Ha Chang, Jeonghun Kim, Jungmin Lee, Juyoung Cho, Man-Seong Park, Shin-Woo Kim, and Dong-Il Won
- Subjects
SARS-CoV-2 ,Immunoglobulin G ,Spike Glycoprotein, Coronavirus ,COVID-19 ,Humans ,Antibodies, Viral ,Antibodies, Neutralizing ,General Biochemistry, Genetics and Molecular Biology - Abstract
To assess protective immunity among a general population against severe acute respiratory syndrome coronavirus 2, the correlation of the commercially available solid-phase assay (SPA) for SARS-CoV-2 IgG with a neutralization assay must be investigated.Both the neutralization assay and SPA were performed on samples of 143 recovered coronavirus disease 2019 (COVID-19) patients. SARS-CoV-2 IgG was measured using two SPAs for the chemiluminescence immunoassay principle with different target proteins: nucleocapsid and spike protein (Architect i2000SR [Abbott] and Liaison XL [DiaSorin], respectively). The plaque reduction neutralization test (PRNT) was conducted to obtain titers for the neutralizing antibody.All patients had PRNT titers ranging from 10 to 2,560. Spike Ab SPA had greater sensitivity than nucleocapsid Ab SPA (81.1% [116/143] and 70.6% [101/143], respectively, p = 0.003). The values measured for both SPAs had a positive correlation with the PRNT titers (both R = 0.77, p0.001). To predict a high PRNT titer (≥ 160), cutoff values of two SPAs were adjusted based on receiver-operating characteristics curve analysis. The nucleocapsid Ab SPA (cutoff index of 4.17) attained 90.3% sensitivity and 75.9% specificity, whereas the spike Ab SPA (cutoff value of 109 unit/mL) attained 87.1% sensitivity and 89.3% specificity. Therefore, the spike Ab SPA had greater specificity than the nucleocapsid Ab SPA (p = 0.003).The qualitative SPA for nucleocapsid Ab, as well as the quantitative SPA for spike Ab, had a modest positive correlation with the neutralization assay. However, spike Ab SPA was more suitable for neutralizing capacity.
- Published
- 2022
38. Performance Evaluation of the BZ COVID-19 Neutralizing Antibody Test for the Culture-Free and Rapid Detection of SARS-CoV-2 Neutralizing Antibodies
- Author
-
Jung Yoon, Suk Yong Lee, Jeonghun Kim, Chae Seung Lim, Man-Seong Park, Bo Kyeung Jung, and Joon-Yong Bae
- Subjects
Medicine (General) ,biology ,Coronavirus disease 2019 (COVID-19) ,SARS-CoV-2 ,Chemistry ,Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) ,Clinical Biochemistry ,COVID-19 ,neutralizing antibodies ,RDT ,ELISA ,Rapid detection ,Molecular biology ,Article ,Confidence interval ,R5-920 ,Dilution ratio ,Neutralization test ,biology.protein ,Antibody ,Neutralizing antibody - Abstract
Rapid and accurate measurement of SARS-CoV-2 neutralizing antibodies (nAbs) can aid in understanding the development of immunity against COVID-19. This study evaluated the diagnostic performance of a rapid SARS-CoV-2 nAb detection test called the BZ COVID-19 nAb test BZ-nAb (BZ-nAb; BioZentech). Using the 90% plaque-reduction neutralization test (PRNT-90) as a reference, 104 serum specimens collected from COVID-19-positive and -negative patients were grouped into 40 PRNT-90-positive and 64 PRNT-90-negative specimens. The performance of the BZ-nAb was compared with that of the cPass surrogate virus neutralization test (cPass sVNT; Genscript). The BZ-nAb showed a sensitivity ranging from 92.5%–95.0% and specificity ranging from 96.9%–100%, whereas cPass sVNT showed a sensitivity of 100% (95% confidence interval (CI) 90.5%–100%) and specificity of 98.4% (95% CI, 91.6%–100%). The dilution factor obtained with PRNT-90 showed a stronger correlation with the percent inhibition of cPass sVNT (r = 0.8660, p < 0.001) compared with the test and control line ratio (T/C ratio) of the BZ-nAb (r = −0.7089, p < 0.001). An almost perfect agreement was seen between the BZ-nAb and cPass sVNT results, with a strong negative correlation between the BZ-nAb T/C ratio and cPass sVNT percent inhibition (r = −0.8022, p < 0.001). In conclusion, the diagnostic performance of the BZ-nAb was comparable to that of the cPass sVNT, although the BZ-nAb had a slightly lower sensitivity.
- Published
- 2021
- Full Text
- View/download PDF
39. Microporous polymers with cascaded cavities for controlled transport of small gas molecules
- Author
-
Won Hee Lee, Ryan P. Lively, Jong Geun Seong, Young Moo Lee, Conrad J. Roos, Hye Jin Jo, Chi Hoon Park, Sun Ju Moon, Kueir-Rarn Lee, Yu Seong Do, Joon Yong Bae, Jong-Myeong Lee, So-Young Lee, Wei-Song Hung, Ju Sung Kim, Juin-Yih Lai, and Yi Ren
- Subjects
Mass flux ,chemistry.chemical_classification ,Multidisciplinary ,Materials science ,Materials Science ,SciAdv r-articles ,Microporous material ,Polymer ,Membrane ,Molecular size ,Chemical engineering ,chemistry ,Molecule ,Physical and Materials Sciences ,Research Article - Abstract
Description, Cascaded microporosity localized on membrane surfaces markedly improved selective transport of small molecules., In membrane-based separation, molecular size differences relative to membrane pore sizes govern mass flux and separation efficiency. In applications requiring complex molecular differentiation, such as in natural gas processing, cascaded pore size distributions in membranes allow different permeate molecules to be separated without a reduction in throughput. Here, we report the decoration of microporous polymer membrane surfaces with molecular fluorine. Molecular fluorine penetrates through the microporous interface and reacts with rigid polymeric backbones, resulting in membrane micropores with multimodal pore size distributions. The fluorine acts as angstrom-scale apertures that can be controlled for molecular transport. We achieved a highly effective gas separation performance in several industrially relevant hollow-fibrous modular platform with stable responses over 1 year.
- Published
- 2021
40. Seroepidemiologic survey of emerging vector-borne infections in South Korean forest/field workers
- Author
-
Hee Jin Cheong, Jin Gu Yoon, Man-Seong Park, Ji Yun Noh, Joon Young Song, Joon Yong Bae, and Woo Joo Kim
- Subjects
Male ,Phlebovirus ,RNA viruses ,Physiology ,RC955-962 ,Social Sciences ,Disease Vectors ,Antibodies, Viral ,Biochemistry ,Geographical locations ,Neutralization ,Medical Conditions ,Ticks ,Sociology ,Seroepidemiologic Studies ,Immune Physiology ,Arctic medicine. Tropical medicine ,Medicine and Health Sciences ,Enzyme-Linked Immunoassays ,Neutralizing antibody ,Pathology and laboratory medicine ,Aged, 80 and over ,Immune System Proteins ,biology ,Eukaryota ,SFTS virus ,Forestry ,Middle Aged ,Medical microbiology ,Infectious Diseases ,Viruses ,Social Systems ,Female ,Pathogens ,Public aspects of medicine ,RA1-1270 ,West Nile virus ,Encephalitis, Tick-Borne ,Encephalitis ,Research Article ,Adult ,Asia ,Severe Fever with Thrombocytopenia Syndrome ,Arthropoda ,Immunology ,Vector Borne Diseases ,Research and Analysis Methods ,Microbiology ,Antibodies ,Encephalitis Viruses, Tick-Borne ,Young Adult ,South Korea ,Republic of Korea ,Arachnida ,medicine ,Humans ,Animals ,Seroprevalence ,Immunoassays ,Aged ,Flaviviruses ,Ixodes ,Organisms ,Viral pathogens ,Public Health, Environmental and Occupational Health ,Tick-borne encephalitis ,Biology and Life Sciences ,Proteins ,Dengue Virus ,medicine.disease ,biology.organism_classification ,Antibodies, Neutralizing ,Invertebrates ,Virology ,Microbial pathogens ,Vector-Borne Diseases ,Species Interactions ,Severe fever with thrombocytopenia syndrome ,Vector (epidemiology) ,Immunologic Techniques ,biology.protein ,People and places ,Zoology - Abstract
With global warming and lush forest change, vector-borne infections are expected to increase in the number and diversity of agents. Since the first report of severe fever with thrombocytopenia syndrome (SFTS) in 2013, the number of reported cases has increased annually in South Korea. However, although tick-borne encephalitis virus (TBEV) was detected from ticks and wild rodents, there is no human TBE case report in South Korea. This study aimed to determine the seroprevalence of TBEV and SFTS virus (SFTSV) among forest and field workers in South Korea. From January 2017 to August 2018, a total 583 sera were obtained from the forest and field workers in South Korea. IgG enzyme-linked immunosorbent assay (ELISA) and neutralization assay were conducted for TBEV, and indirect immunofluorescence assay (IFA) and neutralization assay were performed for SFTSV. Seroprevalence of TBEV was 0.9% (5/583) by IgG ELISA, and 0.3% (2/583) by neutralization assay. Neutralizing antibody against TBEV was detected in a forest worker in Jeju (1:113) and Hongcheon (1:10). Only 1 (0.2%) forest worker in Yeongju was seropositive for SFTSV by IFA (1:2,048) and neutralizing antibody was detected also. In conclusion, this study shows that it is necessary to raise the awareness of physicians about TBEV infection and to make efforts to survey and diagnose vector-borne diseases in South Korea., Author summary With global warming and lush forest change, vector-borne infections are expected to increase in the number and diversity of agents. Since the first report of severe fever with thrombocytopenia syndrome (SFTS) in 2013, the number of reported cases has increased annually in South Korea. However, although tick-borne encephalitis virus (TBEV) was detected from ticks and wild rodents, there is no human TBE case report in South Korea. This study aimed to determine the seroprevalence of TBEV and SFTS virus (SFTSV) among forest and field workers in South Korea. Among 583 forest/field workers, the seroprevalence of neutralizing antibodies against TBEV and SFTSV were 0.3% (2/583) and 0.2% (1/583), respectively. This study shows that it is necessary to raise the awareness of physicians about TBEV infection and to make efforts to survey and diagnose vector-borne diseases in South Korea.
- Published
- 2021
41. Preparation of H1N1 microneedles by a low-temperature process without a stabilizer
- Author
-
Seung Ki Baek, Ga yeong Kim, Hye Rin Jeong, Se Hee Park, Jung-Hwan Park, Joon Yong Bae, Jee Hyun Park, and Man Seong Park
- Subjects
Development environment ,Protective immunity ,Materials science ,Injections, Intradermal ,medicine.medical_treatment ,Pharmaceutical Science ,02 engineering and technology ,engineering.material ,Antibodies, Viral ,030226 pharmacology & pharmacy ,Excipients ,Mice ,03 medical and health sciences ,Influenza A Virus, H1N1 Subtype ,0302 clinical medicine ,Coating ,Neutralization Tests ,medicine ,Animals ,Application methods ,Mice, Inbred BALB C ,Vaccination ,Temperature ,General Medicine ,Drug application ,021001 nanoscience & nanotechnology ,Antibody response ,Influenza Vaccines ,Needles ,Antibody Formation ,engineering ,Female ,Immunization ,0210 nano-technology ,Adjuvant ,Biotechnology ,Stabilizer (chemistry) ,Biomedical engineering - Abstract
During the manufacture of H1N1 microneedles, a stabilizer is usually added to maintain the antigenicity of the vaccine. However, finding a suitable stabilizer is difficult, and the addition of a stabilizer can limit the antigen dose and the addition of an adjuvant because of the limited volume of the microneedles. In this study, the authors evaluated whether H1N1 microneedles could be fabricated without a stabilizer by keeping the production environment at a low temperature. H1N1 microneedle patches without a stabilizer were prepared in a process that involved maintaining a low temperature of 10 °C. The protective immune response to this method of drug application was investigated by comparing it with traditional intramuscular (IM) immunization and with the use of H1N1 microneedles with a stabilizer. A process-sensitive antigen, H1N1, was stabilized without the use of a stabilizer in a process that maintained a low temperature of 10 °C. The preparation process consisted of coating and drying processes. In animal experiments, mice were immunized using an array of low-temperature H1N1 microneedles without a stabilizer (LT-MN), and they showed strong antibody responses. Compared to three other application methods of traditional IM immunization, low-temperature H1N1 microneedles with a stabilizer (LT-MN-T), and room-temperature H1N1 microneedles with a stabilizer (RT-MN-T), LT-MN produced comparable results in inducing protective immunity. A plaque reduction neutralization test found that LT-MN and LT-MN-T provided greater immunity compared with IM and RT-MN-T. A process in which the temperature is maintained at 10 °C can provide successful vaccination with H1N1 microneedles without the addition of a stabilizer. This process can be applied to various temperature-sensitive biologics.
- Published
- 2019
42. Generation and characterization of a monoclonal antibody against MERS-CoV targeting the spike protein using a synthetic peptide epitope-CpG-DNA-liposome complex
- Author
-
Jinsoo Kim, Sony Maharjan, Hyung-Joo Kwon, Man Seong Park, Byoung Kwon Park, Joon Yong Bae, and Su In Lee
- Subjects
Monoclonal antibody ,medicine.drug_class ,Immunoprecipitation ,Lipoplex (O) ,viruses ,Peptide ,Plasma protein binding ,Spike protein ,Biochemistry ,Epitope ,03 medical and health sciences ,Epitopes ,Mice ,MERS-CoV ,Chlorocebus aethiops ,medicine ,Animals ,Humans ,Vero Cells ,Molecular Biology ,chemistry.chemical_classification ,0303 health sciences ,biology ,030302 biochemistry & molecular biology ,Antibodies, Monoclonal ,DNA ,Articles ,General Medicine ,Molecular biology ,chemistry ,Liposomes ,Spike Glycoprotein, Coronavirus ,biology.protein ,Vero cell ,Middle East Respiratory Syndrome Coronavirus ,B cell epitope ,CpG Islands ,Antibody ,Glycoprotein ,Peptides ,Protein Binding - Abstract
Middle East respiratory syndrome coronavirus (MERS-CoV) uses the spike (S) glycoprotein to recognize and enter target cells. In this study, we selected two epitope peptide sequences within the receptor binding domain (RBD) of the MERS-CoV S protein. We used a complex consisting of the epitope peptide of the MERS-CoV S protein and CpG-DNA encapsulated in liposome complex to immunize mice, and produced the monoclonal antibodies 506-2G10G5 and 492-1G10E4E2. The western blotting data showed that both monoclonal antibodies detected the S protein and immunoprecipitated the native form of the S protein. Indirect immunofluorescence and confocal analysis suggested strong reactivity of the antibodies towards the S protein of MERS-CoV virus infected Vero cells. Furthermore, the 506-2G10G5 monoclonal antibody significantly reduced plaque formation in MERS-CoV infected Vero cells compared to normal mouse IgG and 492-1G10E4E2. Thus, we successfully produced a monoclonal antibody directed against the RBD domain of the S protein which could be used in the development of diagnostics and therapeutic applications in the future. [BMB Reports 2019; 52(6): 397-402].
- Published
- 2019
- Full Text
- View/download PDF
43. Amelioration of SARS-CoV-2 infection by ANO6 phospholipid scramblase inhibition
- Author
-
Ju-Ri Sim, Dong Hoon Shin, Pil-Gu Park, So-Hyeon Park, Joon-Yong Bae, Youngchae Lee, Dha-Yei Kang, Ye Jin Kim, Sowon Aum, Shin Hye Noh, Su Jin Hwang, Hye-Ran Cha, Cheong Bi Kim, Si Hwan Ko, Sunghoon Park, Dongkyu Jeon, Sungwoo Cho, Gee Eun Lee, Jeonghun Kim, Young-hye Moon, Jae-Ouk Kim, Jae-Sung Nam, Chang-Hoon Kim, Sungmin Moon, Youn Wook Chung, Man-Seong Park, Ji-Hwan Ryu, Wan Namkung, Jae Myun Lee, and Min Goo Lee
- Subjects
Mammals ,SARS-CoV-2 ,Animals ,Anoctamins ,Humans ,Angiotensin-Converting Enzyme 2 ,Phosphatidylserines ,Phospholipid Transfer Proteins ,Virus Internalization ,General Biochemistry, Genetics and Molecular Biology ,COVID-19 Drug Treatment - Abstract
As an enveloped virus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) delivers its viral genome into host cells via fusion of the viral and cell membranes. Here, we show that ANO6/TMEM16F-mediated cell surface exposure of phosphatidylserine is critical for SARS-CoV-2 entry and that ANO6-selective inhibitors are effective against SARS-CoV-2 infections. Application of the SARS-CoV-2 Spike pseudotyped virus (SARS2-PsV) evokes a cytosolic Ca
- Published
- 2022
44. The Immune Correlates of Orthohantavirus Vaccine
- Author
-
Gee Eun Lee, Mee Sook Park, Jin Il Kim, Man Seong Park, Heedo Park, Joon Yong Bae, and Ki Joon Song
- Subjects
0301 basic medicine ,glycoprotein ,030106 microbiology ,Immunology ,Review ,orthohantavirus ,03 medical and health sciences ,Environmental health ,vaccine ,Drug Discovery ,Pandemic ,Medicine ,Pharmacology (medical) ,Pharmacology ,business.industry ,Transmission (medicine) ,Pandemic preparedness ,pandemic ,030104 developmental biology ,Infectious Diseases ,Orthohantavirus ,Immune correlates ,antigenicity ,business - Abstract
Zoonotic transmission of orthohantaviruses from rodent reservoirs to humans has been the cause of severe fatalities. Human infections are reported worldwide, but vaccines have been approved only in China and Korea. Orthohantavirus vaccine development has been pursued with no sense of urgency due to the relative paucity of cases in countries outside China and Korea. However, the orthohantaviruses continuously evolve in hosts and thus the current vaccine may not work as well against some variants. Therefore, a more effective vaccine should be prepared against the orthohantaviruses. In this review, we discuss the issues caused by the orthohantavirus vaccine. Given the pros and cons of the orthohantavirus vaccine, we suggest strategies for the development of better vaccines in terms of pandemic preparedness.
- Published
- 2021
45. Diagnostic usefulness of subgenomic RNA detection of viable SARS-CoV-2 in patients with COVID-19
- Author
-
Seongman Bae, Hyun Jung Lee, Man-Seong Park, Chunguang Cui, Sung-Han Kim, Joon-Yong Bae, Ji Yeun Kim, Ji-Soo Kwon, Jungmin Lee, Jiwon Jung, Min Jae Kim, Hye Hee Cha, Heedo Park, and Mi Hyun Suh
- Subjects
Microbiology (medical) ,Saliva ,Virus culture ,Infective viral shedding ,SARS CoV-2 ,Biology ,Polymerase Chain Reaction ,Sensitivity and Specificity ,Virus ,Chlorocebus aethiops ,medicine ,Animals ,Humans ,Gene ,Vero Cells ,Subgenomic mRNA ,Viral culture ,SARS-CoV-2 ,COVID-19 ,General Medicine ,Virology ,Infectious Diseases ,Cell culture ,COVID-19 Nucleic Acid Testing ,Vero cell ,Sputum ,RNA, Viral ,Original Article ,subgenomicRNA ,medicine.symptom - Abstract
Objectives The development of a rapid diagnostic test for viable SARS-CoV-2 is important for infection control. Real-time RT-PCR assays detect non-viable virus and cell culture differentiates viable virus but it takes several weeks and is labor-intensive. Subgenomic RNAs may reflect replication-competent virus. We therefore evaluated the usefulness of subgenomic RNAs for diagnosing viable SARS-CoV-2 in patients with COVID-19. Methods Patients with various severities of confirmed COVID-19 were enrolled at a tertiary hospital between February and December 2020. RT-PCR assay results for genomic and subgenomic RNA of SARS-CoV-2 from nasopharyngeal swab, sputum, and saliva specimens were compared with cell culture results. Results A total 189 specimens from 20 COVID-19 patients were tested in genomic and subgenomic PCR assays, and cultured on Vero cells. Of these 189 samples, 62 (33%) gave positive culture results, 93 (49%) negative results, and the remaining 34 (18%) indeterminate results. Compared with cell culture results, the sensitivities of genomic RNA and subgenomic RNA of the N and S genes were comparable as 100%, but the specificity of subgenomic RNA (N, 65% and S, 68%) was higher than that of genomic RNA (N, 23% and S, 17%, p value < 0.001). The mean durations of positive culture and subgenomic RNA were 11.39 ± 10.34 and 13.75 ± 11.22 days after symptom onset (p value = 0.437), respectively, while that of genomic RNA was 22.85 ± 11.83 days after symptom onset (p value < 0.001). Conclusion Our comparison of subgenomic RNA detection with symptom duration and SARS-CoV-2 culture positivity provides a significant advancement on the transmissibility-based approach beyond the detection of SARS-CoV-2 genomic RNA, and warrants further studies on the development of better diagnostic strategy.
- Published
- 2021
46. Duration of Culturable SARS-CoV-2 in Hospitalized Patients with Covid-19
- Author
-
Joon Yong Bae, Chunguang Cui, Min-Chul Kim, Oh Joo Kweon, Seong-Ho Choi, Mi-Kyung Lee, Sun Young Jung, Man Seong Park, Jin-Won Chung, and Kyeong Shin
- Subjects
medicine.medical_specialty ,2019-20 coronavirus outbreak ,Coronavirus disease 2019 (COVID-19) ,Hospitalized patients ,viruses ,Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) ,030204 cardiovascular system & hematology ,Real-Time Polymerase Chain Reaction ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,Correspondence ,medicine ,Humans ,030212 general & internal medicine ,Symptom onset ,Microbial Viability ,SARS-CoV-2 ,business.industry ,Viral culture ,COVID-19 ,General Medicine ,Viral Load ,Hospitalization ,COVID-19 Nucleic Acid Testing ,business ,Viral load - Abstract
Duration of Positive SARS-CoV-2 on RT-PCR and Culture In 21 consecutive patients with confirmed Covid-19, the median times from symptom onset to negative viral culture and negative real-time RT-PCR...
- Published
- 2021
- Full Text
- View/download PDF
47. Highly Permeable Mixed Matrix Membranes of Thermally Rearranged Polymers and Porous Polymer Networks for Gas Separations
- Author
-
Young Moo Lee, Angel E. Lozano, Carla Aguilar-Lugo, Cristina Alvarez, Won Hee Lee, Pedro Prádanos, José G. de la Campa, Joon Yong Bae, Jesús A. Miguel, European Commission, Junta de Castilla y León, Agencia Estatal de Investigación (España), and Korea Institute of Science and Technology
- Subjects
Mixed matrix ,chemistry.chemical_classification ,Polímeros ,Materials science ,Polymers and Plastics ,Polymers ,Process Chemistry and Technology ,Thermal resistance ,Organic Chemistry ,Gas separation ,Polyimides ,Polymer ,Poliimidas ,Mixed matrix membranes ,Membrane ,Chemical engineering ,chemistry ,Thermal rearrangement ,Microporous polymer network ,Membranas de matriz mixta ,Porosity - Abstract
Producción Científica, Mixed matrix membranes (MMMs) have been obtained by blending an aromatic ortho-hydroxypolyimide (PIOH) or an ortho-acetylpolyimide (PIOAc) with different loading amounts (15 and 30 wt %) of a microporous polymer network (PPN), which was obtained from the reaction of triptycene and isatin. The excellent thermal resistance of the PPN (above 500 °C) allowed it to be used as a filler to successfully prepare thermally rearranged polybenzoxazole (TR-PBO)-MMMs obtained from the thermal treatment of the above MMMs. Moreover, PPN showed relatively good compatibility with the polyimide matrix, which improved the TR-PBO formation. The gas separation performances of these MMMs before and after the thermal process were studied for five representative gases (He, O2, N2, CO2, and CH4). For the MMMs derived from ortho-functional polyimides, the gas permeability considerably increased for all of the gases, whereas the selectivity for gas pairs, such as CO2/N2 and CO2/CH4, remained similar. Thus, the selectivity-permeability performance of PIOH- and PIOAc-MMMs containing 30 wt % of PPN (PIOH30 and PIOAc30) surpassed the 1991 Robeson limit for the CO2/CH4 gas pair. In the case of TR-PBO-MMMs (TROH and TROAc-MMMs), the thermal rearrangement process led to an increase in the gas permeability, showing values much better than those observed for the TR-PBO material employed as a MMM matrix. The selectivity values were a little bit lower than the pristine TR-PBO membranes. The CO2 permeability of TROAc30 was 1036 barrer with a CO2/CH4 selectivity of 28, surpassing the 2008 Robeson limit., Agencia Estatal de Investigación - Fondo Europeo de Desarrollo Regional - Unión Europea (projects PID2019-109403RB-C22, CTQ2017-89217-P and PID2019-109403RB-C21), Junta de Castilla y León (project VA224P20), Ministerio de Ciencia, Innovación y Universidades - ICT (project RTI2018-096652-B-I00), Ministry of Trade, Industry & Energy of South Korea.(project 20202020800330)
- Published
- 2021
48. Glycosylation generates an efficacious and immunogenic vaccine against H7N9 influenza virus
- Author
-
Man Seong Park, Jae Soo Shin, Jin Il Kim, Kim Yong Seok, Mee Sook Park, Jun Heo, Joon Yong Bae, Jeonghun Kim, Sunmi Lee, Sehee Park, Kirim Yoo, and Gayeong Kim
- Subjects
0301 basic medicine ,RNA viruses ,Glycosylation ,Physiology ,Cross Protection ,viruses ,Hemagglutinin Glycoproteins, Influenza Virus ,Chick Embryo ,medicine.disease_cause ,Antibodies, Viral ,Influenza A Virus, H7N9 Subtype ,Biochemistry ,Mice ,0302 clinical medicine ,Immunogenicity, Vaccine ,Medical Conditions ,Immune Physiology ,Chlorocebus aethiops ,Influenza A virus ,Medicine and Health Sciences ,Public and Occupational Health ,030212 general & internal medicine ,Biology (General) ,Pathology and laboratory medicine ,Vaccines ,Immune System Proteins ,General Neuroscience ,Viral Vaccine ,Vaccination ,Medical microbiology ,Vaccination and Immunization ,Body Fluids ,Infectious Diseases ,Blood ,Influenza Vaccines ,Viruses ,Pathogens ,Anatomy ,General Agricultural and Biological Sciences ,Research Article ,Infectious Disease Control ,QH301-705.5 ,Guinea Pigs ,Immunology ,Biology ,Cross Reactions ,Microbiology ,General Biochemistry, Genetics and Molecular Biology ,Virus ,Antibodies ,H7N9 ,03 medical and health sciences ,Virology ,Influenza, Human ,Vaccine Development ,medicine ,Animals ,Humans ,Influenza viruses ,Antigens ,Vero Cells ,General Immunology and Microbiology ,Ferrets ,Organisms ,Viral pathogens ,Biology and Life Sciences ,Proteins ,Viral Vaccines ,Blood Serum ,Vaccine efficacy ,Influenza A virus subtype H5N1 ,Viral Replication ,Microbial pathogens ,030104 developmental biology ,HEK293 Cells ,Viral replication ,A549 Cells ,Inactivated vaccine ,Preventive Medicine ,Immune Serum ,Orthomyxoviruses - Abstract
Zoonotic avian influenza viruses pose severe health threats to humans. Of several viral subtypes reported, the low pathogenic avian influenza H7N9 virus has since February 2013 caused more than 1,500 cases of human infection with an almost 40% case-fatality rate. Vaccination of poultry appears to reduce human infections. However, the emergence of highly pathogenic strains has increased concerns about H7N9 pandemics. To develop an efficacious H7N9 human vaccine, we designed vaccine viruses by changing the patterns of N-linked glycosylation (NLG) on the viral hemagglutinin (HA) protein based on evolutionary patterns of H7 HA NLG changes. Notably, a virus in which 2 NLG modifications were added to HA showed higher growth rates in cell culture and elicited more cross-reactive antibodies than did other vaccine viruses with no change in the viral antigenicity. Developed into an inactivated vaccine formulation, the vaccine virus with 2 HA NLG additions exhibited much better protective efficacy against lethal viral challenge in mice than did a vaccine candidate with wild-type (WT) HA by reducing viral replication in the lungs. In a ferret model, the 2 NLG-added vaccine viruses also induced hemagglutination-inhibiting antibodies and significantly suppressed viral replication in the upper and lower respiratory tracts compared with the WT HA vaccines. In a mode of action study, the HA NLG modification appeared to increase HA protein contents incorporated into viral particles, which would be successfully translated to improve vaccine efficacy. These results suggest the strong potential of HA NLG modifications in designing avian influenza vaccines., This study shows that changing the pattern of N-glycosylation of the pathogenic avian influenza H7N9 virus hemagglutinin protein increases the amount of hemagglutinin incorporated into the viral membrane; the candidate vaccine virus induces neutralizing antibodies and protects animal models from lethal viral challenge.
- Published
- 2020
49. MERS-CoV and SARS-CoV-2 replication can be inhibited by targeting the interaction between the viral spike protein and the nucleocapsid protein
- Author
-
Min Young Kim, Dongbum Kim, Won-Keun Kim, Hyung-Joo Kwon, Byoung Kwon Park, Kyeongbin Baek, Man Seong Park, Jinsoo Kim, Younghee Lee, Joon Yong Bae, and Sangkyu Park
- Subjects
0301 basic medicine ,viruses ,Medicine (miscellaneous) ,Peptide ,Plasma protein binding ,spike protein ,Proteomics ,Virus Replication ,Virus ,MERS-CoV ,03 medical and health sciences ,Chlorocebus aethiops ,Animals ,Coronavirus Nucleocapsid Proteins ,Protein Interaction Domains and Motifs ,Pharmacology, Toxicology and Pharmaceutics (miscellaneous) ,Vero Cells ,targeting ,chemistry.chemical_classification ,030102 biochemistry & molecular biology ,SARS-CoV-2 ,virus diseases ,Phosphoproteins ,Virology ,Viral plaque ,In vitro ,Phylogeography ,030104 developmental biology ,chemistry ,Viral replication ,Spike Glycoprotein, Coronavirus ,Vero cell ,Middle East Respiratory Syndrome Coronavirus ,nucleocapsid protein ,Research Paper ,Protein Binding - Abstract
Background: The molecular interactions between viral proteins form the basis of virus production and can be used to develop strategies against virus infection. The interactions of the envelope proteins and the viral RNA-binding nucleocapsid (N) protein are essential for the assembly of coronaviruses including the Middle East respiratory syndrome coronavirus (MERS-CoV). Methods: Using co-immunoprecipitation, immunostaining, and proteomics analysis, we identified a protein interacting with the spike (S) protein in the cells infected with MERS-CoV or SARS-CoV-2. To confirm the interaction, synthetic peptides corresponding to the C-terminal domain of the S protein (Spike CD) were produced and their effect on the interaction was investigated in vitro. In vivo effect of the Spike CD peptides after cell penetration was further investigated using viral plaque formation assay. Phylogeographic analyses were conducted to deduce homology of Spike CDs and N proteins. Results: We identified a direct interaction between the S protein and the N protein of MERS-CoV that takes place during virus assembly in infected cells. Spike CD peptides of MERS-CoV inhibited the interaction between the S and N proteins in vitro. Furthermore, cell penetration by the synthetic Spike CD peptides inhibited viral plaque formation in MERS-CoV-infected cells. Phylogeographic analyses of Spike CDs and N proteins showed high homology among betacoronavirus lineage C strains. To determine if Spike CD peptides can inhibit the replication of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), we used the same strategy and found that the SARS-CoV-2 Spike CD peptide inhibited virus replication in SARS-CoV-2-infected cells. Conclusions: We suggest that the interaction between the S protein and the N protein can be targeted to design new therapeutics against emerging coronaviruses, including SARS-CoV-2.
- Published
- 2020
50. Poly(fluorenyl aryl piperidinium) membranes and ionomers for anion exchange membrane fuel cells
- Author
-
Hae Min Kim, Joon Yong Bae, Eun Seob Sim, Young Moo Lee, Sun Pyo Kim, Won Hee Lee, Jue-Hyuk Jang, Sung Jong Yoo, Yongbing Zhuang, Chuan Hu, Yong-Chae Chung, Nanjun Chen, and Ho Hyun Wang
- Subjects
Alkaline fuel cell ,Multidisciplinary ,Ion exchange ,Science ,Aryl ,General Physics and Astronomy ,Proton exchange membrane fuel cell ,02 engineering and technology ,General Chemistry ,Conductivity ,010402 general chemistry ,021001 nanoscience & nanotechnology ,01 natural sciences ,General Biochemistry, Genetics and Molecular Biology ,Article ,0104 chemical sciences ,chemistry.chemical_compound ,Membrane ,Adsorption ,chemistry ,Chemical engineering ,Copolymer ,0210 nano-technology ,Fuel cells - Abstract
Low-cost anion exchange membrane fuel cells have been investigated as a promising alternative to proton exchange membrane fuel cells for the last decade. The major barriers to the viability of anion exchange membrane fuel cells are their unsatisfactory key components—anion exchange ionomers and membranes. Here, we present a series of durable poly(fluorenyl aryl piperidinium) ionomers and membranes where the membranes possess high OH− conductivity of 208 mS cm−1 at 80 °C, low H2 permeability, excellent mechanical properties (84.5 MPa TS), and 2000 h ex-situ durability in 1 M NaOH at 80 °C, while the ionomers have high water vapor permeability and low phenyl adsorption. Based on our rational design of poly(fluorenyl aryl piperidinium) membranes and ionomers, we demonstrate alkaline fuel cell performances of 2.34 W cm−2 in H2-O2 and 1.25 W cm−2 in H2-air (CO2-free) at 80 °C. The present cells can be operated stably under a 0.2 A cm−2 current density for ~200 h., Developing high-performance anion exchange membranes and ionomers is crucial for low-cost alkaline fuel cells. Here, the authors explore rigid and high ion conductive poly(fluorenyl aryl piperidinium) copolymers, extending their applications to anion exchange membrane fuel cells.
- Published
- 2020
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.